 |
News & Announcements

 Standard & Poor's Stock Report

Merriman Curhan Ford Transitioning Coverage

BRR interview with Dr Jackie Fairley 12th May 2009

ASX Share Price

Nanotechnology on CNBC Squawk Box – Interview with Bernie Marcus
 Analyst Reports

Bioshares Issue 311: Stellar Performance by Leading Australian Biotech Stocks for Start of 2009
18/05/2009

|
|

Starpharma Holdings Limited is a world leader in the development of nanotechnology products for pharmaceutical, life-science and other applications.
Starpharma’s lead product is VivaGel®, a gel-based formulation of a nano-pharmaceutical under development as a vaginal microbicide to prevent the transmission of sexually transmitted infections, including HIV and genital herpes.
VivaGel® is at the expanded safety/Phase IIa stage of clinical development. VivaGel® has been granted Fast Track status by the US Food and Drug Administration (FDA), which will accelerate the clinical and regulatory process. In addition, VivaGel® has been awarded US$20.3 million by the National Institutes of Health (NIH) to progress the development for HIV. The NIH has provided additional funding to develop VivaGel® against genital herpes.
Starpharma has a 100% owned US-based subsidiary Dendritic Nanotechnologies Inc (DNT) expanding the company’s potential products to include drug delivery and industrial specialty chemical applications, many of which have near-term cash-flow opportunities. |